Key result
Irbesartan significantly lowered systolic blood pressure (101 vs 117 mmHg) and body weight, while decreasing adipose leptin mRNA expression in a mouse model of metabolic disorders.
Why the study?
Does irbesartan improve adipose tissue function and metabolic parameters in a mouse model of metabolic disorders?
Does irbesartan improve adipose tissue function and metabolic parameters in a mouse model of metabolic disorders?
In a mouse model of metabolic disorders, irbesartan lowered blood pressure and body weight while suppressing the pro-inflammatory leptin-IL-6 axis in adipose tissue.
Answers are grounded in this paper and cite their sources.
Irbesartan effects remain limited to mice; leaves open translation to human metabolic disease.
Recent studies indicate that the functional renin-angiotensin system (RAS) exists in the adipose tissue. The adipose tissue RAS is proposed in the pathophysiology of metabolic disorders. In the present study, we examined therapeutic effects of irbesartan, an angiotensin II (Ang II) type 1 receptor (AT1R)-specific blocker, in genetically obese diabetic KKAy mice, a model of human metabolic disorders without any dietary loading, with our focus on the analysis on possible effect of irbesartan on the adipose tissue. The treatment with irbesartan significantly lowered systolic blood pressure with a concomitant decrease in body weight in KKAy mice. In addition, irbesartan significantly decreased the adipose leptin mRNA expression and tended to decrease IL-6 mRNA expression in the adipose tissue of KKAy mice. Furthermore irbesartan preserved the adipose gene expression of AT1R-associated protein (ATRAP), an endogenous inhibitory molecule of tissue AT1R signaling, with a concomitant tendency of up-regulation of adipose tissue ATRAP/AT1R ratio. Collectively, these results suggest that the irbesartan-induced beneficial suppressive effect on the leptin-IL-6 axis in the adipose tissue in KKAy mice is partly mediated by a trend of up-regulation of the adipose ATRAP/AT1R ratio as one of pleiotropic effects of irbesartan.
No takes yet. Share an insight, caveat, or question.
Maeda et al. (2014) studied Metabolic disorders (obesity and type 2 diabetes) (n=14). Irbesartan vs. Vehicle was evaluated on Systolic blood pressure at 4 weeks (mmHg) (p=<0.01). Irbesartan significantly lowered systolic blood pressure (101 vs 117 mmHg) and body weight, while decreasing adipose leptin mRNA expression in a mouse model of metabolic disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: